SCHEMBL6089707

SCHEMBL6089707

CCOC(=O)C(C#N)=C1SCC(=O)N1CCO[Si](c1ccccc1)(c1ccccc1)C(C)(C)C

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 7/20 0.43
▸ KMT2A Q03164 5/20 0.43
▸ ALDH1A1 P00352 5/20 0.43
▸ MEN1 O00255 4/20 0.43
▸ LMNA P02545 1/20 0.43
▸ ATM Q13315 1/20 0.43
▸ DHODH Q02127 4/20 0.39
▸ MAPK1 P28482 3/20 0.39
▸ HSD17B10 Q99714 3/20 0.39
▸ NPSR1 Q6W5P4 3/20 0.38
▸ PKM P14618 2/20 0.38
▸ RAB9A P51151 1/20 0.38
▸ KDM4E B2RXH2 2/20 0.37
▸ POLB P06746 1/20 0.37
▸ THRB P10828 1/20 0.37
▸ HIF1A Q16665 1/20 0.37
▸ HPGD P15428 1/20 0.37
▸ L3MBTL1 Q9Y468 1/20 0.37
▸ GAA P10253 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6089701 1.00 MAPT (0.43) MAPTKMT2AALDH1A1MEN1LMNA
SCHEMBL6088005 0.78 MAPT (0.55) MAPTKMT2AALDH1A1MEN1LMNA
SCHEMBL6088011 0.78 MAPT (0.55) MAPTKMT2AALDH1A1MEN1LMNA
SCHEMBL14574219 0.75 MAPT (0.44) MAPTKMT2AALDH1A1MEN1LMNA
SCHEMBL3905983 0.75 MAPT (0.48) MAPTKMT2AALDH1A1MEN1LMNA
SCHEMBL3905980 0.75 MAPT (0.48) MAPTKMT2AALDH1A1MEN1LMNA
SCHEMBL5174362 0.72 MAPT (0.54) MAPTKMT2AALDH1A1MEN1LMNA
SCHEMBL5174367 0.72 MAPT (0.54) MAPTKMT2AALDH1A1MEN1LMNA
SCHEMBL6087023 0.71 MAPT (0.49) MAPTKMT2AALDH1A1MEN1DHODH
SCHEMBL6087029 0.71 MAPT (0.49) MAPTKMT2AALDH1A1MEN1DHODH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060079503-A1 Thiazolidinones and the use therof as polo-like kinase inhibitors SCHERING AKTIENGESELLSCHAFT 2006-04-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060079503-A1 Thiazolidinones and the use therof as polo-like kinase inhibitors PLK4, PLK2, PLK3 MAPT 1138/4885KMT2A 3723/4885ALDH1A1 2553/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback